Advances in PD-1 and PD-L1 inhibitors targeted therapies for NSCLC: Mechanisms, Biomarkers, Combination Therapies
NSCLC is the broadest malignant disease and a significant instigator of cancer-related mortality worldwide. Fortunately, recent advances in precision immunotherapy, particularly those aiming at the PD-1 and PD-L1 pathways, have introduced an encouraging new avenue for the treatment of NSCLC. Neverth...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
EDP Sciences
2025-01-01
|
| Series: | BIO Web of Conferences |
| Online Access: | https://www.bio-conferences.org/articles/bioconf/pdf/2025/25/bioconf_icbb2025_02013.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|